Browsing Category
Pharma Industry News
4730 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
NeuroSense Therapeutics (NASDAQ: NRSN) gets FDA nod for pivotal ALS trial: Is PrimeC nearing commercial breakthrough?
NeuroSense gains FDA clearance for Phase 3 ALS trial of PrimeC, with patient enrollment and global execution plans underway. Find out what comes next.
Novo Nordisk’s Alzheimer’s treatment hopes crash as semaglutide fails to slow cognitive decline
Novo Nordisk’s GLP-1 pill failed in Alzheimer’s trials, raising questions on neurology diversification. Read what this means for its pipeline and stock.
Will Enlivex’s macrophage therapy redefine osteoarthritis care in seniors?
Enlivex posts 6-month knee osteoarthritis trial success with Allocetra, signaling a new era in age-targeted cell therapy. See what comes next.
Can GLP‑1 drugs tackle Alzheimer’s? Novo Nordisk’s setback raises doubts
Can Novo Nordisk challenge Eli Lilly’s GLP-1 lead with Alzheimer’s data? A crucial trial may redefine the future of semaglutide and reshape investor sentiment.
Can immunotherapy finally replace chemo in bladder cancer? Keytruda–Padcev combo shows the way
Explore how Merck’s Keytruda and Padcev combo is redefining bladder cancer treatment without chemo. Survival gains, sector impact, and what’s next in focus.
Citius Oncology (Nasdaq: CTOR) bets on Verix AI to supercharge LYMPHIR’s commercial rollout in CTCL
Find out how Citius Oncology is leveraging Verix AI to power the commercial launch of LYMPHIR and accelerate uptake in CTCL.
OSR Holdings (NASDAQ: OSRH) explores royalty-driven licensing for Vaximm’s cancer therapy
Vaximm may license its oral cancer therapy VXM01 in a deal worth up to $815M. Find out how OSR Holdings plans to turn this into a royalty-driven biotech play.
Can C4 Therapeutics (CCCC) balance dilution and growth with its $400m shelf plan?
C4 Therapeutics files $400M shelf to support oncology trials. Find out what this means for investors and the company’s future strategy.
Australia kills Cosette’s Mayne Pharma (ASX: MYX) buyout—citing drug supply risk and sovereignty
Australia blocks Cosette’s $430M bid to acquire Mayne Pharma, citing critical medicine supply risks. Find out what triggered the decision and future implications.
Bladder cancer breakthrough: Why Keytruda plus Padcev could replace chemo in cisplatin-ineligible patients
Discover how Merck’s Keytruda and Keytruda QLEX with Padcev pave a new pathway in bladder cancer care—read the full story now.